switching between glp 1 agonists chart Comparing Ozempic, Wegovy and Other GLP-1 Drugs Switching between GLP‐1 receptor agonists

Role of receptor phosphorylation in desensitization and internalization of the secretin receptor

Declarations Acknowledgement None

Wu et al., 2020)

The NHANES is normally conducted every two years

Adult patients with T2DM treated by metformin, thiazolidinediones/rosiglitazone or both without adequate glycaemic control after 3 months were enrolled in SUSTAIN 2 trial to explore the comparative effectiveness of semaglutide against sitagliptin

However, these studies are observational, not randomized trials, so we cannot yet interpret the findings as proof of a cancer risk reduction. The review also addressed the question of whether GLP-1s reduce cancer risk because they cause weight loss and improved metabolism, or because they have a direct anti-cancer effect